eISSN: 1897-4309
ISSN: 1428-2526
Contemporary Oncology/Współczesna Onkologia
Current issue Archive Manuscripts accepted About the journal Supplements Addendum Special Issues Editorial board Reviewers Abstracting and indexing Subscription Contact Instructions for authors Publication charge Ethical standards and procedures
Editorial System
Submit your Manuscript
SCImago Journal & Country Rank
Search
Editorial Policies
Sarajevo Declaration on Integrity and Visibility of Scholarly Publications
4/2024
vol. 28
 
Share:
Send email
Share:
Original paper

Prognostic value of FGFR2 in ER-positive breast cancer is influenced by the profile of stromal gene expression: an in silico analysis based on TCGA data

Julia M. Sołek
1
,
Zuzanna Nowicka
2
,
Wojciech Fendler
2
,
Rafal Sadej
3
,
Hanna Romanska
1
,
Marcin Braun
1

  1. Department of Pathology, Chair of Oncology, Medical University of Lodz, Lodz, Poland
  2. Department of Biostatistics and Translational Medicine, Medical University of Lodz, Lodz, Poland
  3. Laboratory of Molecular Enzymology and Oncology, Intercollegiate Faculty of Biotechnology, University of Gdansk and Medical University of Gdansk, Gdansk, Poland
Contemp Oncol (Pozn) 2024; 28 (4): 341–349
DOI: https://doi.org/10.5114/wo.2024.147003
Online publish date: 2025/01/15
Article files
- Prognostic value of FGFR2.pdf  [0.29 MB]
- Prognostic value_Supplementary materials.pdf  [0.88 MB]
Get citation
 
PlumX metrics:
 
1. Campbell TM, Castro MAA, de Santiago I, et al. FGFR2 risk SNPs confer breast cancer risk by augmenting oestrogen responsiveness. Carcinogenesis 2016; 37: 741-750.
2. Braun M, Piasecka D, Tomasik B, et al. Hormonal receptor status determines prognostic significance of FGFR2 in invasive breast carcinoma. Cancers (Basel) 2020; 12: 2713. DOI: 10.3390/cancers­- 12092713.
3. Piasecka D, Braun M, Kitowska K, et al. FGFs/FGFRs-dependent signalling in regulation of steroid hormone receptors – implications for therapy of luminal breast cancer. J Exp Clin Cancer Res 2019; 38: 230. DOI: 10.1186/s13046-019-1236-6.
4. Bohrer LR, Chuntova P, Bade LK, et al. Activation of the FGFR-STAT3 pathway in breast cancer cells induces a hyaluronan-rich microenvironment that licenses tumor formation. Cancer Res 2014; 74: 374-386.
5. Marchini C, Montani M, Konstantinidou G, et al. Mesenchymal/stromal gene expression signature relates to basal-like breast cancers, identifies bone metastasis and predicts resistance to therapies. PLoS One 2010; 5: e14131. DOI: 10.1371/journal.pone.0014131.
6. Frings O, Augsten M, Tobin NP, et al. Prognostic significance in breast cancer of a gene signature capturing stromal PDGF signaling. Am J Pathol 2013; 182: 2037-2047.
7. Turczyk L, Kitowska K, Mieszkowska M, et al. FGFR2-driven signaling counteracts tamoxifen effect on ERalpha-positive breast cancer cells. Neoplasia 2017; 19: 791-804.
8. Castillo-Castrejon M, Sankofi BM, Murguia SJ, et al. FGF1 supports glycolytic metabolism through the estrogen receptor in endocrine-resistant and obesity-associated breast cancer. Breast Cancer Res 2023; 25: 99. DOI: 10.1186/s13058-023-01699-0.
9. Xie Y, Su N, Yang J, et al. FGF/FGFR signaling in health and disease. Signal Transduct Target Ther 2020; 5: 181. DOI: 10.1038/s41392-020-00222-7.
10. Rizzolio S, Giordano S, Corso S. The importance of being CAFs (in cancer resistance to targeted therapies). J Exp Clin Cancer Res 2022; 41: 319. DOI: 10.1186/s13046-022-02524-w.
11. Hegab AE, Ozaki M, Kameyama N, et al. Effect of FGF/FGFR pathway blocking on lung adenocarcinoma and its cancer-associated fibroblasts. J Pathol 2019; 249: 193-205.
12. Wu Y, Yi Z, Li J, et al. FGFR blockade boosts T cell infiltration into triple-negative breast cancer by regulating cancer-associated fibroblasts. Theranostics 2022; 12: 4564-4580.
13. Fernandez-Nogueira P, Mancino M, Fuster G, et al. Tumor-associated fibroblasts promote HER2-targeted therapy resistance through FGFR2 activation. Clin Cancer Res 2020; 26: 1432-1448.
14. Santolla MF, Maggiolini M. The FGF/FGFR system in breast cancer: oncogenic features and therapeutic perspectives. Cancers (Basel) 2020; 12: 3029. DOI: 10.3390/cancers12103029.
15. Solek J, Braun M, Sadej R, Romanska HM. FGFR related phenotypic and functional profile of CAFs in prognostication of breast cancer. Int J Oncol 2024; 65: 94. DOI: 10.3892/ijo.2024.5682.
16. Deng H, Kan A, Lyu N, et al. Dual vascular endothelial growth factor receptor and fibroblast growth factor receptor inhibition elicits antitumor immunity and enhances programmed cell death-1 checkpoint blockade in hepatocellular carcinoma. Liver Cancer 2020; 9: 338-357.
17. Tassi E, Al-Attar A, Aigner A, et al. Enhancement of fibroblast growth factor (FGF) activity by an FGF-binding protein. J Biol Chem 2001; 276: 40247-40253.
18. Bartoschek M, Oskolkov N, Bocci M, et al. Spatially and functionally distinct subclasses of breast cancer-associated fibroblasts revealed by single cell RNA sequencing. Nat Commun 2018; 9: 5150. DOI: 10.1038/s41467-018-07582-3.
19. Anderberg C, Pietras K. On the origin of cancer-associated fibroblasts. Cell Cycle 2009; 8: 1461-1462.
20. Bohrer LR, Schwertfeger KL. Macrophages promote fibroblast growth factor receptor-driven tumor cell migration and invasion in a CXCR2-dependent manner. Mol Cancer Res 2012; 10: 1294-1305.
21. Mao Y, Keller ET, Garfield DH, Shen K, Wang J. Stromal cells in tumor microenvironment and breast cancer. Cancer Metastasis Rev 2013; 32: 303-315.
22. Dey JH, Bianchi F, Voshol J, Bonenfant D, Oakeley EJ, Hynes NE. Targeting fibroblast growth factor receptors blocks PI3K/AKT signaling, induces apoptosis, and impairs mammary tumor outgrowth and metastasis. Cancer Res 2010; 70: 4151-4162.
23. Duhachek-Muggy S, Qi Y, Wise R, et al. Metalloprotease-disintegrin ADAM12 actively promotes the stem cell-like phenotype in claudin-low breast cancer. Mol Cancer 2017; 16: 32. DOI: 10.1186/s12943-017-0599-6.
24. Sugiyama N, Varjosalo M, Meller P, et al. Fibroblast growth factor receptor 4 regulates tumor invasion by coupling fibroblast growth factor signaling to extracellular matrix degradation. Cancer Res 2010; 70: 7851-7861.
25. Ferguson HR, Smith MP, Francavilla C. Fibroblast growth factor receptors (FGFRs) and noncanonical partners in cancer signaling. Cells 2021; 10: 1201. DOI: 10.3390/cells10051201.
26. Polanska UM, Fernig DG, Kinnunen T. Extracellular interactome of the FGF receptor-ligand system: complexities and the relative simplicity of the worm. Dev Dyn 2009; 238: 277-293.
27. Gómez-Cuadrado L, Bullock E, Mabruk Z, Zhao H, Souleimanova M, et al. Characterisation of the stromal microenvironment in lobu­lar breast cancer. Cancers (Basel) 2022; 14: 904. DOI: 10.3390/cancers14040904.
28. Cerami E, Gao J, Dogrusoz U, et al. The cBio cancer genomics portal: an open platform for exploring multidimensional cancer genomics data. Cancer Discov 2012; 2: 401-404.
29. Liu J, Lichtenberg T, Hoadley KA, et al. An integrated TCGA pan-cancer clinical data resource to drive high-quality survival outcome analytics. Cell 2018; 173: 400-416.e411. DOI: 10.1016/ j.cell.2018.02.052.
30. Leerberg DM, Hopton RE, Draper BW. Fibroblast growth factor receptors function redundantly during zebrafish embryonic development. Genetics 2019; 212: 1301-1319.
31. Gorska-Arcisz M, Popeda M, Braun M, et al. FGFR2-triggered autophagy and activation of Nrf-2 reduce breast cancer cell response to anti-ER drugs. Cell Mol Biol Lett 2024; 29: 71. DOI: 10.1186/s11658-024-00586-6.
32. Piasecka D, Kitowska K, Czaplinska D, et al. Fibroblast growth factor signalling induces loss of progesterone receptor in breast cancer cells. Oncotarget 2016; 7: 86011-86025.
33. McLeskey SW, Zhang L, El-Ashry D, et al. Tamoxifen-resistant fibroblast growth factor-transfected MCF-7 cells are cross-resistant in vivo to the antiestrogen ICI 182,780 and two aromatase inhibitors. Clin Cancer Res 1998; 4: 697-711.
34. Mieczkowski K, Kitowska K, Braun M, et al. FGF7/FGFR2-JunB signalling counteracts the effect of progesterone in luminal breast cancer. Mol Oncol 2022; 16: 2823-2842.
35. Mohammed H, Russell IA, Stark R, et al. Progesterone receptor modulates ERalpha action in breast cancer. Nature 2015; 523: 313-317.
36. Ballaré C, Uhrig M, Bechtold T, et al. Two domains of the progesterone receptor interact with the estrogen receptor and are required for progesterone activation of the c-Src/Erk pathway in mammalian cells. Mol Cell Biol 2003; 23: 1994-2008.
37. Campbell TM, Castro MAA, de Oliveira KG, Ponder BAJ, Meyer KB. ERalpha binding by transcription factors NFIB and YBX1 enables FGFR2 signaling to modulate estrogen responsiveness in breast cancer. Cancer Res 2018; 78: 410-421.
38. Denner LA, Weigel NL, Maxwell BL, Schrader WT, O’Malley BW. Regulation of progesterone receptor-mediated transcription by phosphorylation. Science 1990; 250: 1740-1743.
39. Meric-Bernstam F, Bahleda R, Hierro C, et al. Futibatinib, an irreversible FGFR1-4 inhibitor, in patients with advanced solid tumors harboring FGF/FGFR aberrations: a phase I dose – expansion study. Cancer Discov 2022; 12: 402-415.
40. Coombes RC, Badman PD, Lozano-Kuehne JP, et al. Results of the phase IIa RADICAL trial of the FGFR inhibitor AZD4547 in endocrine resistant breast cancer. Nat Commun 2022; 13: 3246. DOI: 10.1038/ s41467-022-30666-0.
41. Alvarez-Fernandez M, Malumbres M. Mechanisms of sensitivity and resistance to CDK4/6 inhibition. Cancer Cell 2020; 37: 514-529.
42. Yang X, Lin Y, Shi Y, et al. FAP Promotes Immunosuppression by cancer-associated fibroblasts in the tumor microenvironment via STAT3-CCL2 signaling. Cancer Res 2016; 76: 4124-4135.
43. Kieffer Y, Hocine HR, Gentric G, et al. Single-cell analysis reveals fibroblast clusters linked to immunotherapy resistance in cancer. Cancer Discov 2020; 10: 1330-1351.
44. Desbois M, Wang Y. Cancer-associated fibroblasts: key players in shaping the tumor immune microenvironment. Immunol Rev 2021; 302: 241-258.
45. Lavie D, Ben-Shmuel A, Erez N, Scherz-Shouval R. Cancer-associated fibroblasts in the single-cell era. Nat Cancer 2022; 3: 793-807.
46. Costa A, Kieffer Y, Scholer-Dahirel A, et al. Fibroblast heterogeneity and immunosuppressive environment in human breast cancer. Cancer Cell 2018; 33: 463-479.e410. DOI: 10.1016/j.ccell. 2018.01.011.
47. Knox S, Merry C, Stringer S, Melrose J, Whitelock J. Not all perlecans are created equal: interactions with fibroblast growth factor (FGF) 2 and FGF receptors. J Biol Chem 2002; 277: 14657-14665.
48. Glabman RA, Choyke PL, Sato N. Cancer-associated fibroblasts: tumorigenicity and targeting for cancer therapy. Cancers (Basel) 2022; 14. DOI: 10.3390/cancers14163906.
49. Bastien RR, Rodríguez-Lescure Á, Ebbert MT, et al. PAM50 breast cancer subtyping by RT-qPCR and concordance with standard clinical molecular markers. BMC Med Genomics 2012; 5: 44. DOI: 10.1186/1755-8794-5-44.
50. Tan PH, Ellis I, Allison K, et al. The 2019 World Health Organization classification of tumours of the breast. Histopathology 2020; 77: 181-185.
Copyright: © 2025 Termedia Sp. z o. o. This is an Open Access article distributed under the terms of the Creative Commons Attribution-NonCommercial-ShareAlike 4.0 International (CC BY-NC-SA 4.0) License (http://creativecommons.org/licenses/by-nc-sa/4.0/), allowing third parties to copy and redistribute the material in any medium or format and to remix, transform, and build upon the material, provided the original work is properly cited and states its license.
FEATURED PRODUCTS
BOOKS
• Genetyka i leczenie chłoniaka rozlanego z dużych komórek B (DLBCL)
Termedia
About us Contact
Copyright notice Privacy policy Advertising policy Contact us
Quick links
Journals Books eBooks Events
© 2025 Termedia Sp. z o.o.
Developed by Bentus.